Post-Thrombolysis Hospital Care: Evidence-Based Updates

Care following intravenous thrombolysis (IVT) is critical to ensure safety, monitor for complications, and begin secondary prevention. Recent trials have reshaped traditional practices. Below is an overview of updated standards, supported by modern evidence.

Updated to reflect the 2026 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke.

1. Neurological Monitoring

Patients receiving tPA should undergo close monitoring in an ICU or step-down unit for the first 24 hours. This includes:

• Neurologic checks (q15 min × 2h, q30 min × 6h, q1h until 24h)
• BP monitoring and management
• Emergent CT if neurological deterioration occurs

2026 Knowledge Gap: The optimal intensity of post-IVT monitoring remains uncertain. The OPTIMIST pilot suggested low-intensity monitoring may be safe in selected patients with mild deficits.

2. Blood Pressure Management

Post-IVT Blood Pressure

ENCHANTED Trial: Compared intensive BP lowering (SBP <140 mmHg) to guideline-based target (SBP <180 mmHg) after thrombolysis. Intensive strategy showed no difference in functional outcome.

2026 Guideline: Intensive SBP reduction is now Class 3: No Benefit. Target SBP <180 mmHg remains standard post-IVT.

Post-EVT Blood Pressure

ENCHANTED2/MT and BEST-II evaluated intensive BP lowering after successful thrombectomy:

• ENCHANTED2/MT: Intensive SBP <120 mmHg showed harm signal — trial stopped early
• BEST-II: SBP <140 vs 140–180 mmHg — no benefit for intensive strategy

3. Glycemic Management

Hyperglycemia is associated with worse outcomes in acute stroke. However, aggressive glucose control has not proven beneficial.

• Class 3: No Benefit: IV insulin to achieve glucose 80–130 mg/dL is NOT recommended
• Avoid hypoglycemia (<60 mg/dL)
• Treat severe hyperglycemia (>180 mg/dL)
• Target range: Moderate control (140–180 mg/dL) is reasonable

4. Early Mobilization

AVERT Trial: Found that very early, frequent mobilization (<24h post-stroke) may worsen outcomes.

Additional Evidence: Several studies suggest that early mobilization between 24–48 hours post-tPA is generally safe, may shorten hospital stay, but has not been shown to significantly impact long-term functional outcomes.

Guideline Update: Delay mobilization for at least 24 hours post-tPA. Initiate rehab once medically stable and neurological status is assessed.

5. Antithrombotic and Anticoagulation Timing

Antiplatelets

• Standard: Withhold aspirin or antiplatelets for 24 hours post-tPA
• CLEAR Trial: Combined low-dose tPA + eptifibatide was safe but not superior

2026 Guideline: Risk of antiplatelet therapy in first 24h post-IVT is uncertain. May be considered if substantial benefit expected (Class 2b).

Anticoagulation for Atrial Fibrillation

ELAN Trial (2023): Early DOAC initiation (≤48h for minor or moderate stroke; day 6–7 for severe) was non-inferior to delayed start, with similar ICH risk.

OPTIMAS Trial (2024): Showed that early initiation (≤4 days) was non-inferior to delayed start (≥7 days) for prevention of recurrent ischemic stroke, with no increase in sICH.

6. DVT and PE Prophylaxis

• IPC devices: Recommended for all non-ambulatory patients immediately
• Pharmacologic prophylaxis: Delay ≥24h post-tPA; reassess hemorrhagic risk

7. Management of Complications

Symptomatic ICH

• Stop thrombolytic infusion immediately
• Emergent labs: CBC, PT/INR, aPTT, fibrinogen, type and crossmatch
• Emergent head CT
• Cryoprecipitate: 10 U IV to target fibrinogen ≥150 mg/dL
• Tranexamic acid: 1000 mg IV over 10 min (or ε-aminocaproic acid 4–5g)
• Neurosurgery and hematology consultation

Orolingual Angioedema

• Maintain airway — prepare for intubation if involving larynx/oropharynx
• Discontinue thrombolytic; hold ACE inhibitors
• Methylprednisolone 125 mg IV + Diphenhydramine 50 mg IV + Famotidine 20 mg IV
• If progressing: Epinephrine 0.3 mL of 0.1% SC or nebulized
• Refractory: Icatibant 30 mg SC or C1 esterase inhibitor 20 IU/kg

8. Transition of Care & Secondary Prevention

• Functional status and rehabilitation planning
• Dysphagia screening before oral intake
• Early secondary prevention (statins, BP meds, DOACs/antiplatelets)
• Stroke education and outpatient follow-up

Summary Table